这里是美国之音慢速英语健康和生活方式报道。
Drug-maker Regeneron Pharmaceuticals announced on Monday it has started late stage human testing of an antibody treatment for COVID-19. It said the tests are designed to show the drug's effectiveness in preventing and treating the disease.
再生元制药公司周一宣布已经开始对一种新冠肺炎抗体疗法进行后期人体测试。该公司表示，这次测试是为了展示该药物在预防和治疗这种疾病方面的效果。
Regeneron is launching one of the drug trials jointly with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The company said the goal is to test the drug's ability to prevent infections in persons who have had close contact with a COVID-19 patient.
再生元公司与美国国家过敏和传染病研究所共同启动一项药物测试。该公司称其目标是测试该药物在预防新冠肺炎密切接触者感染方面的能力。
Regeneron said it hopes the late-stage drug trial will involve about 2,000 patients across the United States.
再生元公司表示，希望这项后期药物试验在美国各地能有约2000名患者参加。
George D. Yancopoulos is a co-founder and president of the New York-based company. He said in a statement, "We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic."
乔治·雅克波罗斯是该公司的联合创始人兼总裁。他在声明中表示，“我们正在进行同步适应性试验，以便即使在持续的全球大流行中，也能尽快提供一种预防和治疗新冠肺炎感染的潜在解决方案。”
Yancopoulos noted that the antibody treatment "could be available much sooner than a vaccine."
雅克波罗斯指出，抗体疗法可能会疫苗要出来得早得多。
Regeneron is holding two separate late stage trials following a positive review from an independent group of REGN-COV2 Phase 1 safety results. The earlier tests involved 30 hospitalized and non-hospitalized patients with COVID-19.
在一组独立的REGN-COV2的1期试验安全性结果得到正面评价之后，再生元公司开始进行两项单独的后期试验。前期测试涉及了30例住院和19例非住院的新冠肺炎患者。
The company said the late-stage Phase 3 prevention trial will take place at about 100 testing centers in the U.S. The aim of the trial is to examine SARS-CoV-2 infection status. SARS-CoV-2 is the virus that cause COVID-19 disease.
该公司表示，后期阶段的3期预防试验将在美国大约100个测试中心进行。该试验的目的是检查新冠病毒的感染状况。新冠病毒是导致新冠肺炎的病毒。
The other Phase 2 and 3 treatment trials are planned across 150 sites in the U.S., Brazil, Mexico and Chile. The trials will include over 1,800 hospitalized and 1,000 non-hospitalized patients.
其它2期和3期治疗试验计划在美国、巴西、墨西哥和智利的150个地点进行。该试验将包括1800例住院患者和1000例非住院患者。
Antibodies are chemical molecules. The body's natural defenses produce antibodies to fight off infection.
抗体是化学分子。人体的自然防御体系会产生抵抗感染的抗体。
The U.S. National Institutes of Health notes that some researchers are testing whether antibodies against COVID-19 could be used as a treatment to others who are infected. Others are studying the structure and work of different antibodies to help guide the development of vaccines.
美国国立卫生研究院指出，一些研究人员正在测试新冠肺炎抗体是否可以用于治疗其他感染者。还有人正在研究不同抗体的结构和作用，以帮助指导疫苗的开发。
There are concerns that the novel coronavirus can change in humans and resist the antibodies.
人们担心新冠病毒会在人体内发生变异并抵抗抗体。
Regeneron's REGN-COV2 treatment combines a "genetically-modified" antibody made by the company and a second antibody from recovered COVID-19 patients.
再生元公司的REGN-COV2疗法结合了该公司生产的“经过基因编辑”的抗体和来自新冠肺炎康复患者的第二种抗体。
The treatment is designed to connect the antibodies to the virus that causes COVID-19 and limit its ability to spread in an infected person. This idea has previously been used to develop drugs to treat other viruses such as HIV, the cause of AIDS.
这种疗法旨在将抗体与导致新冠肺炎的病毒结合，并限制其在感染者中的传播能力。这种理念曾被用于开发药物用于治疗其它病毒，例如导致艾滋病的艾滋病毒。
Yancopoulos noted last month that "individual antibodies, no matter how good, are likely not enough against the devastating virus that causes COVID-19 and the ways it seeks to 'escape' being neutralized."
雅克波罗斯上个月指出，“无论单个抗体有多出色，它都可能不足以抵抗导致新冠肺炎的这种毁灭性病毒，以及阻止它试图避免被中和的途径。
The results of the REGN-COV2 study were published June 15 in Science.
REGN-COV2的研究结果于6月15日发表在《科学》杂志上。
Other drug-makers have begun human trials of their experimental treatments for fighting COVID-19. The companies include Gilead Sciences, Eli Lilly, and AbbVie.
其它制药商已经开始对新冠肺炎的试验性疗法进行人体试验。这些公司包括吉利德科学公司、礼来公司以及雅培生命公司。
And that's the Health and Lifestyle report.
以上就是本期健康和生活方式报道的全部内容。
I'm Anna Matteo.
我是安娜·马特奥。(51VOA.COM原创翻译，禁止转载，违者必究！)